StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Expect the SP to rise over $1.00 going forward

<< Previous

Bullboard Posts

Next >>

Post by gojotv!on Jul 14, 2021 12:48pm

156 Views

Post# 33542764

Expect the SP to rise over $1.00 going forward

That's what no less than three analysts have said, and the revenues support their findings.
Bashers live by the Trump method of lying until it becomes the truth, but shareholders don't have to fall into their game.
Aristotle is the future.
GLTA!

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth